Pharmaceuticals

mRNA Cancer Vaccines And Therapeutics Market Performance Outlook 2026–2030: Revenue to Hit $141.51 Billion at 14.4% CAGR

February 17, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the mrna cancer vaccines and therapeutics market from 2026–2035 with trusted insights from The Business Research Company

What level of CAGR-driven expansion is anticipated in the mRNA Cancer Vaccines And Therapeutics Market between 2026 and 2030?

The mrna cancer vaccines and therapeutics market has expanded considerably in recent years. It is projected to increase from $71.22 billion in 2025 to $82.67 billion in 2026, reflecting a compound annual growth rate (CAGR) of 16.1%. This historic growth is largely attributable to the success of mrna platforms in infectious disease vaccines, ongoing advancements in cancer immunology research, an improved understanding of tumor antigens, early clinical validation of mrna cancer therapies, and increasing public and private funding directed towards oncology innovation.

The mrna cancer vaccines and therapeutics market is anticipated to experience significant expansion over the next few years, with projections indicating a rise to $141.51 billion by 2030, driven by a compound annual growth rate (CAGR) of 14.4%. This projected growth stems from several factors, including the increasing global prevalence of cancer, the escalating demand for tailored and precise cancer treatments, the expansion of mrna manufacturing capabilities, a rise in oncology clinical trials utilizing mrna platforms, and strategic partnerships between biotech and pharmaceutical companies. Key developments expected during this period involve the increasing embrace of personalized cancer vaccines, the broadening application of mrna-based therapeutics beyond oncology, an intensified focus on developing neoantigen-specific vaccines, a growing clinical pipeline for mrna cancer immunotherapies, and greater investment in scalable mrna manufacturing platforms.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17204&type=smp

What Drivers Are Affecting Demand-Supply Dynamics In The mRNA Cancer Vaccines And Therapeutics Market?

The expanding incidence of cancer is projected to stimulate expansion within the mRNA cancer vaccine and therapeutic market moving forward. Cancer itself encompasses a range of illnesses marked by the unregulated proliferation and dissemination of abnormal cells, capable of infiltrating and harming healthy tissues. This escalating occurrence of cancer is primarily linked to elements such as inactive lifestyles, inadequate nutritional practices, and exposure to environmental pollutants, all contributing to an elevated risk of various cancers. mRNA cancer vaccines and therapeutics are vital for enhancing cancer treatment, facilitating tailored, precise immune reactions that aid the body in identifying and eradicating cancerous cells more proficiently, thereby improving patient results. For example, in January 2024, data from the American Cancer Society, Inc., a US-based cancer advocacy organization, indicated that the United States is anticipated to record more than 611,000 cancer-related deaths in 2024, which translates to over 1,600 fatalities daily. Consequently, the increasing burden of cancer is propelling the demand in the mRNA cancer vaccine and therapeutic market.

What Segments Are Included Within The mRNA Cancer Vaccines And Therapeutics Market?

The mrna cancer vaccines and therapeutics market covered in this report is segmented –

1) By Type: Adeno Carcinomas, Mucinous Carcinomas, Adenosquamous Carcinomas

2) By Application: Cancer, Other Applications

3) By End User: Hospitals And Clinics, Ambulatory Surgical Centers, Research Institutes, Other End Users

Subsegments:

1) By Adeno Carcinomas: Lung Adenocarcinomas, Colon Adenocarcinomas, Prostate Adenocarcinomas

2) By Mucinous Carcinomas: Mucinous Ovarian Cancer, Mucinous Breast Cancer, Mucinous Colorectal Cancer

3) By Adenosquamous Carcinomas: Pancreatic Adenosquamous Carcinoma, Cervical Adenosquamous Carcinoma, Esophageal Adenosquamous Carcinoma

Which Trends Are Influencing The Development Of The mRNA Cancer Vaccines And Therapeutics Market?

Leading entities within the mRNA cancer vaccines and therapeutics market are concentrating on creating advanced approaches, including personalized neoantigen vaccines, to boost immune reactions and better survival rates for individuals with cancer. These personalized neoantigen vaccines represent cancer treatments tailored for individual patients, leveraging distinct mutations specific to their tumors to prompt the immune system into identifying and eradicating cancerous cells. An example of this strategy is the collaboration formed in July 2023 between Merck & Co., Inc., a US-based research-focused biopharmaceutical firm, and Moderna Therapeutics, Inc., a US-based biotechnology company. This partnership aims to commence a Phase 3 randomized clinical trial, designated V940-001, to assess mRNA-4157 (V940) when administered alongside KEYTRUDA (pembrolizumab) as an adjuvant therapy for individuals suffering from resected high-risk (Stage IIB-IV) melanoma. The initiation of this study comes after encouraging outcomes from the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial, where the combination demonstrated a significant advantage compared to KEYTRUDA used on its own, by lowering the risks of recurrence and distant metastasis. The objective of the Phase 3 trial is to corroborate these prior findings, with relapse-free survival serving as the primary endpoint and distant metastasis-free survival as the secondary endpoint for evaluation.

Who Are The Top-Performing Companies In The mRNA Cancer Vaccines And Therapeutics Market In Recent Years?

Major companies operating in the mrna cancer vaccines and therapeutics market are BioNTech SE, Moderna Therapeutics Inc., CureVac N.V., Arcturus Therapeutics Holdings Inc., Immatics Biotechnologies GmbH, Argos Therapeutics Inc., Anima Biotech, Translate Bio, eTheRNA Immunotherapies NV, Gritstone bio Inc., Neon Therapeutics, Codiak BioSciences, Cartesian Therapeutics, Replimune Group Inc., Precision BioSciences, Acuitas Therapeutics, Ethris GmbH, Strand Therapeutics, Crown Bioscience, Roche (Hoffmann-La Roche AG)

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/mrna-cancer-vaccines-and-therapeutics-global-market-report

Which Region Currently Holds The Largest Share Of The mRNA Cancer Vaccines And Therapeutics Market?

North America was the largest region in the mRNA cancer vaccination and therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mrna cancer vaccines and therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized mRNA Cancer Vaccines And Therapeutics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=17204&type=smp

Browse Through More Reports Similar to the Global mRNA Cancer Vaccines And Therapeutics Market 2026, By The Business Research Company

Mrna Cancer Vaccines And Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/mrna-cancer-vaccines-and-therapeutics-global-market-report

Therapeutic Bcg Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report

Mrna Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/mrna-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795